Saudi Arabia Brugada Syndrome Market Analysis

Saudi Arabia Brugada Syndrome Market Executive Summary

The Saudi Arabia Brugada Syndrome Market is at around $20.4 Mn in 2023 and is projected to reach $38 Mn in 2030, exhibiting a CAGR of 9.3% during the forecast period.

Brugada syndrome is a rare, but potentially threatening, genetic condition that causes abnormal electrical activity in the heart, leading to an increased risk of sudden cardiac death. People with Brugada syndrome have an increased risk of irregular heart rhythms beginning in the lower chambers of the heart, i.e., the ventricles. Common signs and symptoms associated with Brugada Syndrome include dizziness, fainting, gasping and laboured breathing, particularly at night, irregular heartbeats or palpitations, extremely fast and chaotic heartbeat, and seizures. The risk factors for Brugada syndrome include family history of Brugada syndrome, being male, race, and fever.

Cardiovascular disease (CVD) is a critical public health issue in Saudi Arabia, where it is the leading cause of death as currently, in Saudi Arabia, the annual mortality rate of CVD stands at 294 per 100,000 individuals. The Saudi Arabia Brugada Syndrome Market is driven by significant factors such as growing prevalence of cardiovascular diseases, aging population, and advancements in genetic testing. However, high cost of treatment, side effects and complications of treatment, and limited R&D restrict the growth and potential of the market.

The major players of the Saudi Arabia Brugada Syndrome Market are Jamjoom Pharma, Baxter, Riyadh Pharma, Sanofi, Novartis, and AstraZeneca, among others.

Market Dynamics

Market Growth Drivers

Growing Prevalence of Cardiovascular Diseases: In Saudi Arabia, cardiovascular disease (CVD) is the primary cause of death, accounting for around 45.7% of all fatalities. As a result of aging populations, changing lifestyles, and rising rates of diabetes and hypertension, cardiovascular problems are becoming more widespread, and hereditary illnesses like Brugada syndrome are receiving more attention. Because of its increased incidence, healthcare systems are investing more on Brugada syndrome-specific research, diagnostic tools, and cutting-edge therapies. As a result, demand increases which propels market expansion.

Aging Population: The proportion of people in Saudi Arabia aged 60 or more is predicted to be 25% of the total population by the end of 2050. As the population grows older, the incidence of cardiovascular diseases, including rare conditions like Brugada syndrome, rises. Older adults are more prone to arrhythmias and other heart issues, leading to a higher demand for specialized diagnostics and treatments for Brugada syndrome. This demographic trend boosts the need for advanced healthcare solutions such as genetic testing, early diagnosis, and targeted therapies, driving market growth.

Advancements in Genetic Testing: Advancements in genetic testing are a major driver of growth in the Brugada syndrome market. The development of more advanced and affordable genetic testing technologies has made it easier to identify individuals with Brugada syndrome or those at risk. Improved accuracy and accessibility of these tests enable earlier diagnoses, facilitating timely intervention and better management of the condition. As genetic testing becomes increasingly routine in healthcare, healthcare providers and patients gain greater awareness, resulting in higher diagnosis rates. This surge in early and accurate detection of Brugada syndrome cases increases the demand for specialized treatments and monitoring solutions, thus boosting market expansion.

Market Restraints

High Cost of Treatment: The high costs of diagnosing and treating Brugada syndrome represent a significant challenge to market growth. Advanced treatments like implantable cardioverter defibrillators (ICDs) and specialized genetic tests are often expensive, restricting their accessibility for many patients, particularly those in low- and middle-income classes. This financial barrier limits access to essential care and treatment, impeding timely diagnosis, early intervention, and effective management of Brugada syndrome, which in turn hampers the overall growth of the market.

Side Effects and Complications of Treatments: The growth of the Brugada syndrome market, including treatment options like implantable cardioverter defibrillators (ICDs), is significantly constrained by the side effects and complications. Patients face issues such as infections, device malfunctions, and psychological effects, which can discourage them from opting for these treatments. These risks can lead to lower acceptance and adoption rates of advanced therapies, thereby limiting market expansion even when effective treatment options are available.

Limited R&D: Limited research of rare diseases significantly impede the growth of the Brugada syndrome market. As a relatively rare condition, Brugada syndrome attracts less investment compared to more prevalent cardiovascular diseases, leading to slower progress in understanding the disease, developing new diagnostic tools, and creating innovative treatments. This lack of investment results in fewer medical breakthroughs, restricting the availability of effective therapies and diagnostic methods and, in turn, constraining the overall growth of the Brugada syndrome market.

Regulatory Landscape and Reimbursement Scenario

The regulatory authority in charge of the pharmaceuticals in the Saudi Arabia is the Saudi Food and Drug Authority (SFDA). It is responsible for ensuring the safety and efficacy of drugs and other health related products sets post-marketing criteria and controls the distribution of pharmaceutical products in Saudi Arabia.

Clinical Trial Administration was formed in 2009 and its primary responsibilities are to evaluate the clinical trials protocol, conduct inspections based on Good Clinical Practice (GCP), and maintain the Saudi Clinical Trial Registry (SCTR). The applications submitted by the pharmaceutical companies is verified by the SFDA to ensure compliance with rules and completeness after rigorous assessment, testing, and inspection. Prior to authorization, an internal price agreement must be formed and a Certificate of Pharmaceutical Product (CPP) must be obtained at the time of registration. Applications may be reviewed after two to six months, but priority products are removed from the queue.

The Ministry of Health (MoH) is in charge of managing certain facets of private insurance as well as the public healthcare system. The Saudi General Organization for Social Insurance (SAGO) offers health insurance to those who work for the government and their families. For covering the public sector, the MoH employs a variety of techniques, such as diagnosis-related groups (DRGs) and fee-for-service (FFS). FFS pays providers according to the services they offer, whereas DRGs establish a fixed fee for treating a particular illness. For the private sector, FFS, capitation (fixed payments per insured individual), and bundled payments (set price for a period of treatment) are only a few of the techniques used by private insurance companies.

Competitive Landscape

Key Players

Here are some of the major key players in the Saudi Arabia Brugada Syndrome Market:

• Jamjoom Pharma
• Baxter
• Riyadh Pharma
• Sanofi
• Novartis
• AstraZeneca
• Pfizer
• Medtronic
• GE Healthcare
• Novo Nordisk